0001209191-16-135066.txt : 20160802 0001209191-16-135066.hdr.sgml : 20160802 20160802185103 ACCESSION NUMBER: 0001209191-16-135066 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160801 FILED AS OF DATE: 20160802 DATE AS OF CHANGE: 20160802 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kite Pharma, Inc. CENTRAL INDEX KEY: 0001510580 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 BUSINESS PHONE: (310) 824-9999 MAIL ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wiezorek Jeffrey CENTRAL INDEX KEY: 0001610823 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36508 FILM NUMBER: 161801871 MAIL ADDRESS: STREET 1: C/O KITE PHARMA, INC. STREET 2: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-08-01 0 0001510580 Kite Pharma, Inc. KITE 0001610823 Wiezorek Jeffrey C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404 0 1 0 0 SVP Clinical Development Common Stock 2016-08-01 4 M 0 1500 6.89 A 16367 D Common Stock 2016-08-01 4 S 0 891 56.66 D 15476 D Common Stock 2016-08-01 4 S 0 609 57.24 D 14867 D Employee Stock Option (Right to Buy) 6.89 2016-08-01 4 M 0 1500 0.00 D 2024-06-05 Common Stock 1500 80708 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2016. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.01 to $56.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.05 to $57.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the 175,000 shares subject to the stock option vested and became exercisable on May 5, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. /s/ David M. Tanen, Attorney-in-Fact 2016-08-02